Summary
6.73 0.03(0.45%)05/16/2024
Kala Pharmaceuticals Inc (KALA)
Kala Pharmaceuticals Inc (KALA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.59 | 3.37 | -7.48 | 1.00 | 6.50 | -55.38 | -98.07 | -35.62 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.05 | |
| Open | 7.03 | |
| High | 7.17 | |
| Low | 6.74 | |
| Volume | 17,066 | |
| Change | 0.11 | |
| Change % | 1.59 | |
| Avg Volume (20 Days) | 7,463 | |
| Volume/Avg Volume (20 Days) Ratio | 2.29 | |
| 52 Week Range | 5.10 - 19.31 | |
| Price vs 52 Week High | -63.49% | |
| Price vs 52 Week Low | 38.24% | |
| Range | 0.28 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 19 | |
| EBIDTA | -84,957,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 8.50 | |
| Book Value | 0.9440 | |
| Earnings Per Share | -2.0330 | |
| EPS Estimate Current Quarter | -0.4200 | |
| EPS Estimate Next Quarter | -0.3900 | |
| EPS Estimate Current Year | -1.8700 | |
| EPS Estimate Next Year | -1.2900 | |
| Diluted EPS (TTM) | -2.0330 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -9.5865 | |
| Return on asset (TTM) | -0.3325 | |
| Return on equity (TTM) | -1.5063 | |
| Revenue TTM | 11,622,000 | |
| Revenue per share TTM | 0.1870 | |
| Quarterly Revenue Growth (YOY) | 0.3820 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 4,189,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.6943 | |
| Revenue Enterprise Value | 7.4580 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 65,500,300 | |
| Shares Float | 42,429,113 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.97 | |
| Institutions (%) | 51.24 | |
05/14 16:05 EST - globenewswire.com
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases --
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases --
04/04 10:56 EST - zacks.com
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
The mean of analysts' price targets for KALA BIO (KALA) points to a 152.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
03/29 08:00 EST - globenewswire.com
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
02/26 08:00 EST - globenewswire.com
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also be available for one-on-one meetings on Monday, March 4, 2024.
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also be available for one-on-one meetings on Monday, March 4, 2024.
01/19 16:01 EST - globenewswire.com
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
11/13 10:32 EST - zacks.com
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA BIO (KALA) came out with a quarterly loss of $3.41 per share versus the Zacks Consensus Estimate of a loss of $2.15. This compares to earnings of $19.25 per share a year ago.
11/13 08:00 EST - globenewswire.com
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM award, expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
09/05 08:00 EST - GlobeNewsWire
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference.
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded presentation will be made available beginning on Monday, September 11, 2023 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference.
08/04 08:00 EST - globenewswire.com
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED -- -- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases -- -- As of June 30, 2023, $59.2 million in cash, cash equivalents and short-term investments; together with $15.0 million CIRM award expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarded $15 million grant by California Institute for Regenerative Medicine (CIRM) to support ongoing KPI-012 program for the treatment of PCED -- -- Rebranded to KALA BIO, Inc. reflecting focus on advancing biologics for the treatment of rare, serious ophthalmic diseases -- -- As of June 30, 2023, $59.2 million in cash, cash equivalents and short-term investments; together with $15.0 million CIRM award expected to fund operations into 2Q 2025 -- ARLINGTON, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.
08/02 16:01 EST - globenewswire.com
KALA BIO to Participate in Upcoming Investor Conferences in August
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will participate in the following investor conferences in August 2023:
KALA BIO to Participate in Upcoming Investor Conferences in August
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will participate in the following investor conferences in August 2023:
07/19 16:01 EST - globenewswire.com
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
06/02 08:00 EST - globenewswire.com
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference being held in New York, NY. Members of Kala's management team will participate in a fireside chat on Friday, June 9, 2023 at 11:55 a.m. ET. Management will also be available for one-on-one meetings on Friday, June 9, 2023.
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference being held in New York, NY. Members of Kala's management team will participate in a fireside chat on Friday, June 9, 2023 at 11:55 a.m. ET. Management will also be available for one-on-one meetings on Friday, June 9, 2023.
05/09 08:00 EST - globenewswire.com
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designation for KPI-012 for the treatment of PCED -- -- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designation for KPI-012 for the treatment of PCED -- -- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
04/28 08:00 EST - globenewswire.com
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect (PCED). The grant includes funding for the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial as well as product and process characterization and analytical development for the program.
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect (PCED). The grant includes funding for the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial as well as product and process characterization and analytical development for the program.
04/13 12:56 EST - zacks.com
KALA Up on Fast Track Designation to Lead Ocular Candidate
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
KALA Up on Fast Track Designation to Lead Ocular Candidate
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
03/27 08:00 EST - globenewswire.com
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial -- -- Topline data for Cohort 2 targeted for 1Q 2024; if positive, trial could potentially serve as first of two pivotal trials required to support submission of a BLA -- ARLINGTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The first cohort enrolled two patients, treated with a high dose of KPI-012 (3 U/mL) four times per day (QID). Both patients successfully completed at least one week of dosing with no safety issues observed. The trial will now advance to Cohort 2.
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial -- -- Topline data for Cohort 2 targeted for 1Q 2024; if positive, trial could potentially serve as first of two pivotal trials required to support submission of a BLA -- ARLINGTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED). The first cohort enrolled two patients, treated with a high dose of KPI-012 (3 U/mL) four times per day (QID). Both patients successfully completed at least one week of dosing with no safety issues observed. The trial will now advance to Cohort 2.
03/24 11:27 EST - zacks.com
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
03/21 13:00 EST - zacks.com
4 Biotech Stocks to Consider for Your Portfolio in 2023
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
4 Biotech Stocks to Consider for Your Portfolio in 2023
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
03/20 10:45 EST - zacks.com
Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.
Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.